Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
Study Details
Study Description
Brief Summary
Green tea extract contains ingredients that may prevent or slow the growth of prostate cancer. This phase I trial is studying how well green tea extract works in treating patients with prostate cancer undergoing surgery to remove the prostate
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
PRIMARY OBJECTIVES:
- Determine the bioavailability of defined green tea catechin extract in prostate tissue after treatment with defined green tea extract in patients with prostate cancer.
SECONDARY OBJECTIVES:
-
Determine the effect of this treatment on changes in clusterin levels and matrix metalloproteinase (MMP)-2 and MMP-9 in prostate tissue from these patients.
-
Determine the effect of this treatment on changes in serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in these patients.
-
Determine the effect of this treatment on changes in oxidative DNA damage in peripheral blood leukocytes in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive oral defined green tea catechin extract daily for 4-7 weeks.
Arm II: Patients receive oral placebo daily for 4-7 weeks.
All patients undergo surgery one day after the last dose of study agent.
Biopsies are taken at the time of surgery. Plasma and tissue catechin levels are measured with high performance liquid chromatography (HPLC). 8OHdG levels in peripheral blood are measured with HPLC and mass spectometry. Immunohistochemistry is used to measure matrix metalloproteinase (MMP)-2, MMP-9, and clusterin. Insulin-like growth factor (IGF)-1 and IGF binding protein-3 are measured with immunoenzyme techniques.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm I (green tea catechin extract) Patients receive oral defined green tea catechin extract daily for 4-7 weeks. All patients undergo surgery one day after the last dose of study agent. |
Dietary Supplement: defined green tea catechin extract
Given orally
Other Names:
Other: immunohistochemistry staining method
Correlative studies
Other Names:
Other: immunoenzyme technique
Correlative studies
Other Names:
Other: laboratory biomarker analysis
Correlative studies
Procedure: biopsy
Undergo biopsy
Other Names:
Other: mass spectrometry
Correlative studies
Other: high performance liquid chromatography
Correlative studies
Other Names:
|
| Placebo Comparator: Arm II (placebo) Patients receive oral placebo daily for 4-7 weeks. All patients undergo surgery one day after the last dose of study agent. |
Drug: placebo
Given orally
Other Names:
Other: immunohistochemistry staining method
Correlative studies
Other Names:
Other: immunoenzyme technique
Correlative studies
Other Names:
Other: laboratory biomarker analysis
Correlative studies
Procedure: biopsy
Undergo biopsy
Other Names:
Other: mass spectrometry
Correlative studies
Other: high performance liquid chromatography
Correlative studies
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Post-treatment green tea catechin concentration levels in prostate tissue [Up to 6 weeks]
Descriptive statistics will be performed on prostate tissue EGCG within each intervention group. The difference in concentration levels between the two intervention groups will be tested using a two-group t-test at a one-sided 0.05 level of significance. If the distributions are not symmetrical, a non-parametric Wilcoxon test will be considered. The percentage of patients positive for EGCG in prostate tissue will be compared between the intervention groups using a Fisher's exact test of proportions at a one-sided 0.05 level of significance.
Secondary Outcome Measures
- Changes in clusterin, matrix metalloproteinase (MMP)-2, and MMP-9 levels [Baseline to post-treatment]
Will be compared between intervention groups using a two-group t-test with a 0.05 two-sided significance level; with a sample size of 23 patients per group, there will be over 90% power to detect a difference equal to an effect size of 1.0. If the distributions are not symmetrical, a non-parametric Wilcoxon test will be considered. Correlations among the various biomarkers, as well as between post-intervention EGCG concentrations and changes in biomarker levels, will be explored (using Pearson or Spearman Rank correlation coefficients as appropriate).
- Changes in Serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein-3 [Baseline to post-treatment]
Will be compared between intervention groups using a two-group t-test with a 0.05 two-sided significance level; with a sample size of 23 patients per group, there will be over 90% power to detect a difference equal to an effect size of 1.0. If the distributions are not symmetrical, a non-parametric Wilcoxon test will be considered. Correlations among the various biomarkers, as well as between post-intervention EGCG concentrations and changes in biomarker levels, will be explored (using Pearson or Spearman Rank correlation coefficients as appropriate).
- Change in ratio of 8OHdG:dG [Baseline to post-treatment]
Statistical analysis will focus on the change scores (defined as changes from baseline to post-intervention). Changes in the Polyphenon E group will be compared with those in the placebo group, using a two-sided t-test.
- Change in plasma levels of EGCG [Baseline to post-treatment]
Will be compared between groups, and the correlation of plasma and prostate tissue levels will be examined; however, plasma levels are expected to be low because of the washout during pre-operative fasting. Additional exploratory analyses will investigate the correlation of EGCG tissue levels with adherence during the intervention period (assessed primarily by capsule counts).
Eligibility Criteria
Criteria
Criteria:
-
Biopsy-proven adenocarcinoma of the prostate meeting the following criteria: organ-confined disease; treatable by prostatectomy
-
PSA < 50 ng/mL
-
ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%
-
Bilirubin normal
-
AST and ALT normal
-
Creatinine normal
-
Fertile patients must use effective contraception
-
No uncontrolled intercurrent illness including, but not limited to, any of the following: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; psychiatric illness or social situations that would limit study compliance
-
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extract
-
No prior therapy for prostate cancer (i.e., hormone therapy, radiation therapy, or surgery)
-
No systemic treatment (chemotherapy) and/or radiation therapy for any malignancy within the past 5 years (excluding nonmelanoma skin cancer or cancer confined to organs with surgical removal as the only treatment)
-
No regular tea consumption (> 6 servings of hot tea or 12 servings of iced tea or equivalent combination per week) within the past month
-
No other concurrent investigational agents
-
No other concurrent consumption of tea or tea-derived products from green, black, or oolong tea
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Arizona Cancer Center - Tucson | Tucson | Arizona | United States | 85724-5024 |
Sponsors and Collaborators
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Frederick Ahmann, Arizona Cancer Center - Tucson
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NCI-2009-00894
- HSC # 06-0695-04
- N01CN35158
- CDR0000538554